---
title: "The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic"
description: "Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)"
section: market-watch
published: 2026-11-02T05:12:12.258984+00:00
canonical: https://valorandventures.media/article/01b2b390-9ce3-4f06-aad7-0380318ea5fd
publisher: "Valor & Ventures Media"
source: "Bloomberg"
source_url: https://www.bloomberg.com/news/videos/2026-11-02/the-icelandic-dna-behind-amgen-s-hunt-for-the-next-ozempic
access: free
---

# The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic

*Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)*

## Executive Summary

Biopharmaceutical manufacturer Amgen is mounting an effort to establish a presence within the intensely competitive obesity therapy sector, drawing upon scientific origins located in Iceland, according to reporting by Bloomberg. The company’s prospective pathway into this market originated from biological resources maintained in sub-zero cold storage at minus-13 degrees Fahrenheit, housed within a subterranean research site at Reykjavík's University of Iceland Science Park. This scientific initiative positions the company to compete against blockbuster therapies such as Ozempic, which have rapidly redefined global commercial expectations in weight management. As detailed by Bloomberg correspondent Madison Muller, Amgen's approach illustrates how specialized population genetics can serve as the foundational architecture for therapeutic discovery. Drawing upon deep genetic data enables researchers to investigate distinct biological targets that traditional screening methods might fail to capture. The commercial stakes within metabolic therapeutics remain exceptionally high, requiring pharmaceutical contenders to differentiate their pipelines from incumbent market leaders. The outlet reports that breaking into this specialized field requires solid scientific rationale to challenge entrenched market alternatives. By tracing its research back to the localized biological material preserved in Reykjavík, Amgen seeks to establish a distinct mechanism capable of challenging existing formulations. For executives, entrepreneurs, and life sciences innovators, Amgen’s trajectory illustrates the strategic value of long-term data curation in modern enterprise development. Navigating disruptive commercial opportunities frequently demands integrating specialized, localized scientific assets into global corporate scaling mechanisms. Observing how major corporate players translate discrete biological research into commercial applications offers vital perspective on innovation, competitive differentiation, and long-range development strategy.

## Article

Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)
---
Bloomberg

---

Originally published by Bloomberg: https://www.bloomberg.com/news/videos/2026-11-02/the-icelandic-dna-behind-amgen-s-hunt-for-the-next-ozempic